M Holdings Securities Inc. lifted its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 16.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 19,234 shares of the biopharmaceutical company’s stock after buying an additional 2,719 shares during the period. M Holdings Securities Inc.’s holdings in Bristol-Myers Squibb were worth $1,072,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Blue Chip Partners Inc. increased its holdings in Bristol-Myers Squibb by 0.7% in the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 15 shares during the last quarter. Jackson Grant Investment Advisers Inc. increased its holdings in Bristol-Myers Squibb by 0.4% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock valued at $218,000 after purchasing an additional 15 shares during the last quarter. Shayne & CO. LLC increased its holdings in Bristol-Myers Squibb by 0.6% in the 2nd quarter. Shayne & CO. LLC now owns 4,041 shares of the biopharmaceutical company’s stock valued at $225,000 after purchasing an additional 24 shares during the last quarter. Chilton Investment Co. LLC increased its holdings in Bristol-Myers Squibb by 0.5% in the 2nd quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock valued at $294,000 after purchasing an additional 26 shares during the last quarter. Finally, Greenleaf Trust increased its holdings in Bristol-Myers Squibb by 0.4% in the 2nd quarter. Greenleaf Trust now owns 9,608 shares of the biopharmaceutical company’s stock valued at $535,000 after purchasing an additional 39 shares during the last quarter. Institutional investors and hedge funds own 69.82% of the company’s stock.

Several analysts recently weighed in on BMY shares. UBS reiterated a “buy” rating and issued a $72.00 target price (up previously from $62.00) on shares of Bristol-Myers Squibb in a report on Friday, October 6th. Vetr upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 target price for the company in a report on Monday, October 9th. Zacks Investment Research downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. BMO Capital Markets reiterated a “sell” rating and issued a $49.00 target price on shares of Bristol-Myers Squibb in a report on Monday, September 4th. Finally, Citigroup lifted their target price on shares of Bristol-Myers Squibb to $72.00 and gave the company a “buy” rating in a report on Wednesday, October 18th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $64.93.

In other news, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction on Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the sale, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of Bristol-Myers Squibb stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total transaction of $335,172.00. Following the sale, the executive vice president now directly owns 9,251 shares of the company’s stock, valued at $585,033.24. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.

Bristol-Myers Squibb Company (NYSE:BMY) opened at $62.41 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46. Bristol-Myers Squibb Company has a 1 year low of $46.01 and a 1 year high of $66.10. The company has a market cap of $101,688.18, a P/E ratio of 20.99, a price-to-earnings-growth ratio of 2.36 and a beta of 1.18.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The business had revenue of $5.25 billion during the quarter, compared to analysts’ expectations of $5.20 billion. During the same period in the prior year, the business earned $0.77 EPS. The business’s quarterly revenue was up 6.7% on a year-over-year basis. equities research analysts forecast that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be given a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 2.56%. The ex-dividend date is Thursday, January 4th. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 61.42%.

ILLEGAL ACTIVITY WARNING: “Bristol-Myers Squibb Company (BMY) Stake Increased by M Holdings Securities Inc.” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://www.watchlistnews.com/bristol-myers-squibb-company-bmy-stake-increased-by-m-holdings-securities-inc/1767456.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.